INDSWFTLAB · NSE
Ind-Swift Laboratories Limited
₹317.05
-3.98% (-₹13.15)
Prev. close
₹330.2
Volume
4,84,691
Delivery %
49.8%
As of
20 Nov 2026
Price history
Analyst sentiment
No analyst stances in this range
0 analyst stances · last 90 days · one per analyst
Try a wider range.
Explore by date range →Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Bullish on Ind-Swift Laboratories, advising investors to buy, hold, and accumulate the stock. He expects an upside of 21…” | Rajesh PalviyaAxis Securities | Ind-Swift Laboratories Ltd | HIT |
Fundamentals
About Ind-Swift Laboratories Limited
Ind-Swift Laboratories Limited, together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients (APIs), intermediates, and formulations in India and internationally. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, Parkinson's disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, alcohol abstinence, antineoplastic, ADHD symptoms, anticancer, hypercholesterolemia, antimuscarinic, antimigraine, and thrombocytopenia. It also provides reference standards and impurities for acamprosate calcium, anastrozole, aripiprazole, atorvastatin calcium, azithromycin dihydrate, bexarotene, cinacalcet hydrochloride, clopidogrel bisulphate, clopidogrel hydrochloride, dapoxetine hydrochloride, donepezil hydrochloride, ezetimibe, fexofenadine hydrochloride, imatinib mesylate, ivabradine hydrochloride, ivabradine oxalate, letrozole, mecloxamine citrate, naratriptan hydrochloride, nateglinide, nitazoxanide, nitrosamine, pazopanib hydrochloride, quetiapine hemifumarate, raltegravir potassium, ropinirole hydrochloride, rosuvastatin calcium, saxagliptin monohydrate, silodosin, and temozolomide, as well as contract research and manufacturing services. The company exports its products. Ind-Swift Laboratories Limited was incorporated in 1995 and is based in Manimajra, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Navrattan R. Munjal
Headquarters
Manimajra
Employees
1,388
Website
indswiftlabs.comExchange
View on NSE ↗Key stats
Market cap
₹3,274.24 Cr
P/E ratio (TTM)
38.4
Dividend yield
0.00%
EPS (TTM)
₹9.64
Beta (1Y · daily vs NIFTY 50)
0.71
Beta (5Y · monthly vs NIFTY 50)
0.94
Shares float
3.22 Cr
EPS · quarter ended Jun 2026
₹2.84
Financial Performance
01 · Financials
Net income is omitted from this chart: coverage begins inside the plotted window, and every plotted period must carry a complete point set — the P&L table below has the available figures. Net income ÷ revenue is not drawn for FY22 (no net income reported).
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
Left off as not meaningful (growth from a very small base, beyond ±400%): Fixed assets FY25 (+3313%).
05 · Capital Structure & Asset Utilization
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹856.58 Cr | ₹1,038.73 Cr | ₹1,207.31 Cr | ₹1,709.15 Cr | ₹561.71 Cr | ₹641.29 Cr | |
EBITDA | ₹203.62 Cr | ₹239.10 Cr | ₹230.28 Cr | ₹776.43 Cr | ₹285.20 Cr | ₹81.06 Cr |
| ₹-4.40 Cr | — | ₹47.60 Cr | ₹538.75 Cr | ₹250.48 Cr | ₹43.12 Cr | |
Diluted EPS | ₹-0.74 | ₹-0.36 | ₹-4.28 | ₹91.18 | ₹35.21 | ₹5.03 |
Net income has filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Net income for Mar 2021 could not be checked against the company's own annual report: this page shows ₹-4.40 Cr while the annual report gives ₹-3.15 Cr (28.4% apart). That disagreement leaves the whole cross-check inconclusive, so Net income for Mar 2020 (the annual report alone gives ₹-21.19 Cr) and Net income for Mar 2022 (the annual report alone gives ₹-2.15 Cr) are left blank here too, rather than shown from only one of the two sources.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹1,818.00 Cr | ₹1,801.00 Cr | ₹1,824.00 Cr | ₹1,165.00 Cr | ₹1,438.00 Cr | ₹1,673.00 Cr | |
| — | ₹952.99 Cr | ₹862.10 Cr | ₹216.80 Cr | ₹32.98 Cr | ₹17.91 Cr | |
Stockholders' equity | ₹604.00 Cr | ₹601.00 Cr | ₹682.00 Cr | ₹931.00 Cr | ₹1,173.00 Cr | ₹1,384.00 Cr |
Current assets, Trade receivables, Cash & equivalents, Non-current assets, CWIP, Others, Total debt, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹135.00 Cr | ₹150.00 Cr | ₹195.00 Cr | ₹-163.00 Cr | ₹-25.00 Cr | ₹-70.00 Cr | |
Investing cash flow | ₹-10.17 Cr | ₹4.77 Cr | ₹-13.37 Cr | ₹-27.15 Cr | ₹-113.13 Cr | ₹-72.68 Cr |
| ₹-124.00 Cr | ₹-141.00 Cr | ₹-186.00 Cr | ₹699.00 Cr | ₹69.00 Cr | ₹142.00 Cr | |
Capital expenditure | ₹-10.68 Cr | ₹-18.41 Cr | ₹-12.77 Cr | ₹-73.01 Cr | ₹-64.41 Cr | ₹-87.72 Cr |
End cash position | — | — | ₹17.07 Cr | ₹477.19 Cr | ₹425.11 Cr | ₹429.85 Cr |
End cash position has filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21–Dec 24(15Q) | Mar 25–Jun 25(3Q) | Jul 25 | Jul 25 | Aug 25 | Aug 25–Dec 25(3Q) | Feb 26 | Mar 26 | Jun 26 |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 42.00% | 40.94% | 38.57% | 36.77% | 37.72% | 39.50% | 43.06% | 42.99% | 42.93% |
| Public | 58.00% | 59.06% | 61.43% | 63.23% | 62.28% | 60.50% | 56.94% | 57.01% | 57.07% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.25 L Cr | ₹1,769.9 | 38.8 | 5.09 | 13.7% | 0.06 | +11.9% | +3.7% |
| Divi's Laboratories Limited | ₹2.66 L Cr | ₹10,037.5 | 90.8 | 15.85 | 15.3% | 0.00 | +12.3% | +47.5% |
| Torrent Pharmaceuticals Limited | ₹1.79 L Cr | ₹4,738.5 | 79.4 | 21.31 | 25.8% | 1.79 | +21.5% | +32.5% |
| Laurus Labs Limited | ₹1.27 L Cr | ₹2,348 | 94.8 | 23.94 | 16.8% | 0.48 | +22.0% | +146.2% |
| Apollo Hospitals Enterprise Limited | ₹1.23 L Cr | ₹8,599.5 | 58.8 | 12.95 | 20.5% | 0.90 | +15.7% | +10.1% |
| Zydus Lifesciences Limited | ₹1.19 L Cr | ₹1,188.1 | 26.7 | 4.40 | 18.6% | 0.46 | +18.4% | +22.3% |
| Lenskart Solutions Limited | ₹1.16 L Cr | ₹689.7 | 181.4 | 13.30 | 5.6% | 0.35 | +35.4% | — |
| Dr. Reddy's Laboratories Limited | ₹1.14 L Cr | ₹1,374 | 40.6 | 3.02 | 11.4% | 0.21 | +3.2% | +14.5% |
| Cipla Limited | ₹1.13 L Cr | ₹1,402 | 38.9 | 3.27 | 11.3% | 0.02 | +2.1% | -6.7% |
| Mankind Pharma Limited | ₹1.03 L Cr | ₹2,475 | 45.9 | 6.31 | 11.7% | 0.39 | +17.0% | +3.1% |
| Aurobindo Pharma Limited | ₹98,101.93 Cr | ₹1,705 | 26.6 | 2.59 | 9.2% | 0.21 | +6.4% | +48.4% |
| Ind-Swift Laboratories Limited | ₹3,037.43 Cr | ₹370.55 | 35.7 | 2.19 | 3.1% | 0.01 | +11.4% | +264.7% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Ind-Swift Laboratories Ltd Q2 PAT Rises 3.5 Times to ₹31.03 Crore
Multibagg AI · 12 days ago
Ind-Swift Laboratories Ltd (BOM:532305) (Q2 2027) Earnings Call Highlights: PAT Surges 3. ...
Yahoo Finance Australia · 16 days ago